Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2007

View Archived Issues

Snapshots of clinical trials in cardiology

Orally bioavailable anthracycline penetrates the CNS in mice

Novel agents for HIV infection reported in recent Pfizer patent

Ccr2 protective in Alzheimer's disease

Genetic studies allow creation of test for clozapine-induced agranulocytosis risk

Clevudine metabolism studied in human hepatocytes

New therapeutic options for hepatitis C described in recent patent literature

Novel therapeutic agents for neurological disorders reported in recent patents

Cerus presents preclinical data on two new L. monocytogenes-based immunotherapeutics

Further analysis of CRD5 phase I/II data

ACE and NMRC begin Campylobacter challenge study

Syndax licenses selective HDAC inhibitor from Bayer Schering Pharma

Thallion updates progress of FDA Advisory Committee meeting on STEC infection

Galapagos signs new collaborations with Ono

AGI receives FDA approval for phase III study of arverapamil

Bayer and WHO sign agreement for Lampit provision for Chagas disease

MultiCell signs supply agreement with Lundbeck

Pevion and Mymetics sign virosome technology license agreement

TopoTarget to acquire Apoxis

Multikinase inhibitor from Amgen with antiangiogenic and antitumor activity

LY-2401401, a new multikinase inhibitor, presented at the AACR meeting

VEGFR inhibitor with potent antitumor activity alone and in combination

Novel series of substituted pyrroles shows promise for the treatment of breast cancer

Eisai completes Morphotek acquisition

Renvela meets primary endpoint in hyperphosphatemic patients

BNC-105, a vascular disruption agent with an improved therapeutic index

Merck seeks new indications for Gardasil for vaginal and vulvar cancers

Once-weekly formulation of risedronate sodium approved in Japan

Avastin approved in Japan for advanced or recurrent colorectal cancer

Reclast approved for Paget's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...